Drug Trial Radar · NCT03737812
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
Last checked: Nov 19, 2026Latest source record: Dec 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
123
Actual
Start
Feb 27, 2019
Primary completion
Jan 15, 2021
Study completion Aug 30, 2021
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Nov 13, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).
Conditions
- Multiple Sclerosis (MS)
Interventions
elezanumabDrug
solution for infusion
placeboDrug
solution for infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Overall Response Score (ORS)Time frame: Week 52
Locations
37 sites in 2 countries. Site status is shown where the registry gives one.
St. Josephs Hospital and Med Center /ID# 202809
Phoenix, Arizona
Sutter East Bay Medical Foundation-Jordon Research and Education Dev. Inst. /ID# 202448
Berkeley, California
The Research Center of Southern California /ID# 202802
Carlsbad, California
Vladimir Royter MD /ID# 202483
Hanford, California
Stanford MS Center /ID# 202445
Palo Alto, California
UC Davis Health-Neurological Surgery /ID# 202485
Sacramento, California
UCSF School of Medicine - Neurology /ID# 203194
San Francisco, California
University of Colorado School of Medicine, Dept of Neurology /ID# 202807
Aurora, Colorado
Advanced Neurosciences Research, LLC /ID# 203072
Fort Collins, Colorado
Rowe Neurology Institute /ID# 202744
Lenexa, Kansas
Duplicate_Parexel International /ID# 202747
Baltimore, Maryland
International Neurorehabilitation Institute /ID# 213333
Lutherville, Maryland
Michigan Institute for Neurological Disorders (MIND) /ID# 202470
Farmington Hills, Michigan
Memorial Neurological Institute and Center for Multiple Sclerosis /ID# 206327
Owosso, Michigan
Ridgeview Specialty Clinic Chaska - Neurology /ID# 204384
Chaska, Minnesota
Washington University-School of Medicine /ID# 202899
St Louis, Missouri
The MS Center for Innovations in Care at Missouri Baptist Medical Center /ID# 205432
St Louis, Missouri
Cleveland Clinic Lou Ruvo Cent /ID# 204744
Las Vegas, Nevada
Oklahoma Med Res. Foundation /ID# 203442
Oklahoma City, Oklahoma
Providence Neurological Specialties - West /ID# 203193
Portland, Oregon
Advanced Neurosciences Institute /ID# 204555
Franklin, Tennessee
KCA Neurology - Franklin /ID# 202912
Franklin, Tennessee
Neurology Consultants of Dallas - LBJ Fwy /ID# 203102
Dallas, Texas
Central Texas Neurology Consul /ID# 203108
Round Rock, Texas
Integrated Neurology Services /ID# 202743
Alexandria, Virginia
Evergreen Neuroscience Institute /ID# 204205
Kirkland, Washington
Virginia Mason Medical Center /ID# 205439
Seattle, Washington
Swedish MS Center /ID# 202904
Seattle, Washington
West Virginia Univ School Med /ID# 202849
Morgantown, West Virginia
Froedtert Memorial Lutheran Hospital /ID# 202618
Milwaukee, Wisconsin
University of British Columbia - MS & NMO Clinical Trials Group, Djavad Mowafagh /ID# 203536
Vancouver, British Columbia, Canada
Duplicate_London Health Sciences Centre - University Hospital /ID# 203538
London, Ontario, Canada
Ottawa Hospital Research Institute /ID# 203058
Ottawa, Ontario, Canada
Unity Health Toronto - St. Michael's Hospital /ID# 206213
Toronto, Ontario, Canada
Recherche Sepmus Inc. /ID# 212852
Greenfield Park, Quebec, Canada
Centre Hospitalier de l'Universite de Montreal - CRCHUM /ID# 203869
Montreal, Quebec, Canada
Montreal Neurological Institut /ID# 203868
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.